<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>New-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> after transplantation is recognized as one of the metabolic consequences which may increase the risk of morbidity and mortality after solid organ transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The pathophysiology of new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> after transplantation has not been clearly defined and may resemble that of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, characterized by predominantly <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> or defective insulin secretion, or both </plain></SENT>
<SENT sid="2" pm="."><plain>This review aims to summarize the current state of knowledge regarding the prevalence, consequences, pathogenesis, and management of new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> after transplantation, with a major focus on the possible mechanisms involved in the pathogenesis of the disorder </plain></SENT>
<SENT sid="3" pm="."><plain>The aetiology of new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> after transplantation is multifactorial, with diabetogenic immunosuppressive drugs playing a major role </plain></SENT>
<SENT sid="4" pm="."><plain>Multiple cellular and physiologic mechanisms are involved in the process </plain></SENT>
<SENT sid="5" pm="."><plain>Selection of an appropriate maintenance immunosuppressive regimen should involve balancing the risk of patient and graft survival vs. the potential for new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> after transplantation </plain></SENT>
</text></document>